Thank you to the entire Vida Ventures, LLC team but especially to Helen S. Kim and Alex Loftis for the invitation to join you today for your LP meeting. It was a real treat to speak on Rajul Jain’s panel alongside some amazing colleagues in industry Scott Garland Amir Nashat & Laura Shawver about the hard work we are all doing to advance promising new medicines for patients in need. I am proud that Avalyn Pharma is a Vida portfolio company, and deeply appreciative of all you do to support our mission.
Avalyn Pharma
生物技术研究
Cambridge，Massachusetts 4,165 位关注者
Targeted therapies for rare lung diseases
关于我们
Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis
- 网站
-
https://www.avalynpharma.com
Avalyn Pharma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
地点
-
主要
获取路线
US，Massachusetts，Cambridge，02142
Avalyn Pharma员工
动态
-
We’re excited that our CEO Lyn Baranowski has joined their Board of Advisors for Life Science Cares, Inc. We are equally thrilled to start collaborating with LSC Boston network as a corporate partner! This collaboration underscores our commitment to making a positive impact in our community.
We’re excited to announce that Avalyn Pharma has recently joined Life Science Cares Boston's Network of Good as a Corporate Partner! And they are jumping right in to planning a weeklong off-site in Cleveland, visiting Cleveland Clinic and doing team-building activities, and they are excited to give back to the community through their partnership with LSC during the off-site. LSC Boston is a nonprofit that activates the financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in our communities. LSC Boston envisions all of our neighbors having access to basic needs, education, and opportunity. Avalyn has made a multiplier investment to LSC Boston, which helps provide funding to LSC Boston’s 32 nonprofit partners. Thank you, Avalyn Pharma, and welcome to the #NetworkofGood!
-
-
We’re pleased to announce the appointment of Heather Turner as the new Chair of our Board of Directors! Heather brings over 25 years of legal, operational and strategic leadership experience in life science companies, most recently serving as the CEO of Carmot Therapeutics, Inc.. Her extensive experience will bring invaluable insights for Avalyn. Welcome aboard, Heather! Read more: https://lnkd.in/ebwsH2G8
-
-
What an incredible experience at the Pulmonary Fibrosis Foundation Education Summit the last two days! It was an inspiring event filled with insightful presentations, engaging discussions, and a strong sense of community. Our CEO, Lyn Baranowski, gave an overview of our lead program AP01, an optimized inhaled formulation of pirfenidone, being developed for the treatment of #PulmonaryFibrosis. Thank you to the Pulmonary Fibrosis Foundation team and everyone who joined us.
-
-
We’re excited to participate in multiple investor conferences this November in London. Join us to learn more about our progress in developing innovative inhaled therapies for patients with #PulmonaryFibrosis and rare #LungDiseases.???? ???? Learn more: https://lnkd.in/eFmKVCu5
-
-
As National Healthy Lung Month comes to a close, Avalyn Pharma remains dedicated to continuing the conversation about lung health and raising awareness about pulmonary fibrosis (PF). At Avalyn, we’re committed to advancing innovative inhaled therapies to improve the lives of those affected by pulmonary fibrosis and other interstitial lung diseases. We encourage you to learn more about pulmonary fibrosis and the importance of recognizing its symptoms. ? #HealthyLung #PulmonaryFibrosis #LungHealth #Avalyn #NationalHealthyLungMonth
-
-
Our team, in collaborative efforts with Brainomix, presented at #ICLAF in Athens last week, sharing analyses on Brainomix's e-Lung biomarkers as well as an association between functional improvement and anatomical changes from the completed Phase 1b ATLAS study evaluating AP01 in patients with idiopathic pulmonary fibrosis. #ICLAF #pulmonaryfibrosis
?? Last week at #ICLAF in Athens we joined our partners Avalyn Pharma to present a study where our AI-enabled lung imaging biomarkers were applied to objectively and independently quantify efficacy for a novel therapeutic: https://lnkd.in/em2CajsJ Learn more about our Life Sciences business here ???? https://lnkd.in/ehB-SukQ You can also learn more about our proprietary lung imaging biomarkers here ???? https://lnkd.in/exux3Ep9
-
Our CEO, Lyn Baranowski, has been named to the PharmaVoice 100 list for 2024! ? Recognized among biotech trailblazers, visionaries, and leaders, Lyn’s commitment to innovation, respiratory medicine, and patients is inspiring. ? Join us in congratulating Lyn on this well-deserved recognition and read more about her and her fellow honorees here: https://lnkd.in/eaGKF5zB ? #PV100 #LifeSciences #Pharma #PharmaVoice100 #PharmaLeaders
-
-
This past weekend, Team Avalyn came together to participate in the National Walk Day for Pulmonary Fibrosis. ???? Whether walking in local parks, city streets, or scenic trails, our team demonstrated unity and dedication to raising awareness and supporting those affected by pulmonary fibrosis. #PulmonaryFibrosis #NationalWalkDay #TeamAvalyn #MakingADifference
-
The Avalyn team is at the European Investigators Meeting for our global Phase 2b MIST study of AP01 (inhaled pirfenidone) in progressive #pulmonaryfibrosis. We are delighted to partner with the expert study coordinators, nurses, and clinicians to reach patients who might benefit from our investigational therapy. Learn more at www.mistppfstudy.com #TeamAvalyn #MISTstudy #lungdiseases #clinicaltrials
-